Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 109 clinical trials
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCR /CD19 Depleted HSCT

The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T

bone marrow procedure
residual disease
residual tumor
acute leukemia
lymphoid leukemia
  • 24 Jan, 2021
Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell

chronic leukemias
acute leukemias
chronic leukemia
shortening fraction
  • 24 Feb, 2021
  • 1 location
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD)

The investigators propose to determine the engraftment and transplant related morbidity and mortality after a non-myeloablative allogeneic hematopoietic stem cell transplant protocol using

carbon monoxide
  • 28 Jan, 2021
  • 1 location
A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I

proportion of subjects alive at age 2 (24 months) and at least 1-year post-infusion without allogeneic hematopoietic stem cell transplant (HSCT) and characterization of the safety and toxicity associated

  • 25 Jan, 2021
  • 1 location
Sorafenib Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

This phase I/II trial studies the best dose of sorafenib when given together with busulfan and fludarabine in treating patients with acute myeloid leukemia that has come back or does not respond to treatment and who are undergoing donor stem cell transplant. Sorafenib may stop the growth of cancer cells …

carbon monoxide
ejection fraction
mycophenolate mofetil
direct bilirubin
  • 23 Jan, 2021
  • 2 locations
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell transplant (allo-HCT). The geriatric assessment includes looking

  • 03 Mar, 2021
  • 7 locations
IS-free Treg HaploHCT

myelodysplastic syndromes (MDS) receiving a haploidentical donor allogeneic hematopoietic stem cell transplant (HSCT). The names of the study interventions involved in this study are:

  • 11 Feb, 2021
  • 1 location
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML MDS and MDS/MPN

/myeloproliferative neoplasm-unclassifiable (MDS/MPN-unclassifiable) and are planning to have an allogeneic hematopoietic stem cell transplant ("bone marrow transplant"). The goal of this research study is to (1

human chorionic gonadotropin
chronic myelomonocytic leukemia
transplant conditioning
residual tumor
  • 30 Jan, 2021
  • 1 location
Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients

High dose chemotherapy and radiation used as preparative regimens in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) disrupts intestinal homeostasis by damaging the

allogeneic hematopoietic stem cell transplant
acute graft-versus-host disease
graft versus host disease
bone marrow transplant
  • 25 Jan, 2021
  • 1 location
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic agent called ozogamicin. Inotuzumab ozogamicin attaches to B cell-specific CD22 cancer cells in a targeted …

residual tumor
monoclonal protein
tyrosine kinase inhibitor
lymphoid leukemia
  • 05 Mar, 2021
  • 2 locations